Scil Proteins GmbH Named Winner of the "Großer Preis des Mittelstandes" Competition  
9/25/2012 10:39:05 AM

Halle (Germany), 25th September 2012 - Scil Proteins GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, announced today that it was awarded the "Großer Preis des Mittelstandes” by the Oskar Patzelt Foundation. After reaching a finalist place last year, in 2012 Scil Proteins was distinguished as one of four winners among the 213 nominated companies in Saxony-Anhalt.

The award winners and finalists from Berlin, Brandenburg, Mecklenburg-Vorpommern, Saxony and Saxony-Anhalt received the prize on September 22nd in Dresden in the presence of Deputy Prime Minister of Saxony, Sven Morlok, and Kurt Biedenkopf, Saxony's retired Prime Minister.

Nationwide, a total of 3,589 companies were nominated and the key selection criteria for the prize were:

• outstanding overall development of the company,

• creation as well as security of jobs and apprentice positions,

• exemplary performance in the competition criteria "Innovation/Modernization", "Regional Engagement" and "Service/Customer focus/Marketing".

Dr. Ulrike Fiedler, CEO of Scil Proteins, commented: "I am delighted that Scil Proteins won the 2012 award. Our 122 employees daily bring their know-how into the production of protein-based therapeutics as well as advancement of our own Affilin® drug candidates, thus we are continuously working towards improving the patients’ quality of life. Furthermore, I think that our efforts to support young, talented scientists by the Rainer-Rudolph-Foundation and our two German scholarships have been recognized by this award."

Scil Proteins was nominated by the office for the promotion of trade and industry of the City of Halle (Saale) for this competition three times and was awarded as winner 2012 for the first time.

About Scil Proteins

Scil Proteins is a biopharmaceutical company working with industry partners in the development and manufacture of protein therapeutics and diagnostics as well as discovering and developing proprietary Affilin® molecules. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer. Scil Proteins discovery platform is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. In the context of technology and development partnerships, this technology is also available to the industry. The company has a longstanding expertise in protein production and development and offers GMP contract biomanufacturing and process development to biotech and pharma companies. With state of the art equipment and a particular expertise at refolding proteins, Scil Proteins has an excellent track record in supplying a top level support for its partners. Scil Proteins has supported a number of different pharma and biotech companies in process development and biomanufacturing. Scil Proteins is a well-established private company located in Halle, Germany.


Dr. Ulrike Fiedler


Scil Proteins GmbH

t: +49 (0) 345 27 99 63 30


Dr. Robert Mayer

Account Director

College Hill Life Science

t: +49 (0) 89 52 38 8030